Advertisement

Topics

Congenital Heart DiseasePipeline Insights, 2017 [Updated: 30052017] Prices from USD $1063

09:12 EDT 19 Jun 2017 | BioPortfolio Reports

DelveInsight's, Congenital Heart DiseasePipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Congenital Heart Disease. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Preclinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA EMA designations details. DelveInsight's Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Congenital Heart Disease. DelveInsight's Report also assesses the Congenital Heart Disease therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as uptodate as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.
Scope
The report provides competitivepipeline landscape of Congenital Heart Disease
The report provides pipeline products under drug profile section which includes product description, MOA, licensors collaborators, development partner and chemical information
Coverage of the Congenital Heart Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for Congenital Heart Disease and also provide company profiling
The report also gives the information of dormant and discontinued pipeline projects
Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Delivery Time 4872 Hours

Original Article: Congenital Heart DiseasePipeline Insights, 2017 [Updated: 30052017] Prices from USD $1063

NEXT ARTICLE

More From BioPortfolio on "Congenital Heart DiseasePipeline Insights, 2017 [Updated: 30052017] Prices from USD $1063"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Congenital Diseases
Congenital conditions are those which are present from birth. They include structural deformities or loss of function in organs such as the <!--LGfEGNT2Lhm-->heart, gut or skeletal system. They can be corrected by <!--LGfEGNT2Lhm-->surgery, m...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...